EHA 2019 | Dasatinib-blinatumomab for ALL

Robin Foà

Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses a dasatinib-blinatumomab combination for the frontline treatment of adult Philadelphia positive acute lymphoblastic leukemia (ALL). Speaking from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Prof. Foà discusses preliminary results of the GIMEMA LAL2116 D-ALBA trial (NCT02744768).

Share this video